Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Mar 23, 2006

TAXOTERE® receives U.S. FDA approval for use in advanced stomach cancer

TAXOTERE(R)-based regimen demonstrates a 23% reduction in the risk of mortality in patients with advanced stomach cancer
Mar 20, 2006

Statement responding to recent media reports regarding appropriate use of AMBIEN® (zolpidem tartrate) CIV in the U.S.
Mar 12, 2006

New study furthers understanding of the role of dual antiplatelet therapy in the prevention of atherothrombotic events, including heart attack, stroke or cardiovascular death in broad population

Certain subgroups may benefit from dual therapy, for others it should be avoided
Feb 28, 2006

APIDRA® - a new rapid-acting insulin analog - is now available in the United States for hyperglycemia in adults with type 2 and type 1 diabetes

New prandial insulin with the OptiClik(R) delivery system can work with longer-acting insulins, such as basal insulin Lantus(R), providing a complementary approach to glucose control
Feb 24, 2006

Sanofi-aventis reports strong growth of 25.7% in 2005 adjusted EPS - Nearly 90% of synergies delivered by end 2005 - Dividend increased by 26.7%

Sanofi-aventis Reports Strong Growth of 25.7% in 2005 Adjusted EPS(1); Nearly 90% of synergies delivered by end 2005; Dividend increased by 26.7%

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.